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Near-death experiences (NDEs) are complex subjective experiences, which have been
previously associated with the psychedelic experience and more specifically with
the experience induced by the potent serotonergic, N,N-Dimethyltryptamine (DMT).
Potential similarities between both subjective states have been noted previously,
including the subjective feeling of transcending one’s body and entering an alternative
realm, perceiving and communicating with sentient ‘entities’ and themes related to
death and dying. In this within-subjects placebo-controled study we aimed to test the
similarities between the DMT state and NDEs, by administering DMT and placebo to 13
healthy participants, who then completed a validated and widely used measure of NDEs.
Results revealed significant increases in phenomenological features associated with the
NDE, following DMT administration compared to placebo. Also, we found significant
relationships between the NDE scores and DMT-induced ego-dissolution and mystical-
type experiences, as well as a significant association between NDE scores and baseline
trait ‘absorption’ and delusional ideation measured at baseline. Furthermore, we found
a significant overlap in nearly all of the NDE phenomenological features when comparing
DMT-induced NDEs with a matched group of ‘actual’ NDE experiencers. These results
reveal a striking similarity between these states that warrants further investigation.




“Scared of dying, I guess. Of falling into the void”.
“They say you fly when you die”.
(Feature film: ‘Enter the Void’).
INTRODUCTION
Near-death experiences (NDEs) are complex experiential episodes that occur in association with
death or the perception that it is impending (Moody, 1975; Greyson, 1983). Prospective studies
with cardiac arrest patients indicate that the incidence of NDEs vary between 2–18% depending on
what criteria are used to determine them (Parnia et al., 2001; Van Lommel et al., 2001; Schwaninger
et al., 2002; Greyson, 2003). Although there is no universally accepted definition of the NDE,
common features include feelings of inner-peace, out-of-body experiences, traveling through a
dark region or ‘void’ (commonly associated with a tunnel), visions of a bright light, entering
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into an unearthly ‘other realm’ and communicating with sentient
‘beings’ (Moody, 1975; Ring, 1980; Greyson, 1983; Martial
et al., 2017). Reviewing the phenomenology of NDEs, we
have been struck by similarities with the experience evoked
by the classic serotonergic psychedelic N,N-Dimethyltryptamine
(DMT) (Strassman et al., 1994; Strassman, 2001).
Commonly described features of the DMT experience include
a feeling of transcending one’s body and entering into an
alternative ‘realm’, an acoustic perception of a high pitched
‘whining/whirring’ sound during the onset of the experience,
perceiving and communicating with ‘presences’ or ‘entities’,
plus reflections on death, dying and the after-life (Sai-Halász
et al., 1958; Strassman, 2001; Gouzoulis-Mayfrank et al.,
2005). Furthermore, the reported vividness of both subjective
experiences have led to NDE experiencers and DMT users
describing the states they enter as ‘realer than real’ (for NDEs
see Moody, 1975; Thonnard et al., 2013; for DMT see Strassman,
2001).
The term near-death exerpience (NDE) was coined by
philosopher Raymond Moody more than 40 years ago (Moody,
1975). Remarkably, the overlap between the phenomenology of
the classic serotonergic psychedelic experience and NDEs was
highlighted by Moody himself more than 4 decades ago (Moody,
1975) and these similarities have formed the basis of a popular
hypothesis on the pharmacology of NDEs, i.e., that endogenous
DMT is released in significant concentrations during the dying
process (Strassman, 2001), but see (Nichols, 2017) for a critique
of this hypothesis. The psychological state produced by the DMT-
containing Amazonian brew, ayahuasca (the literal translation of
‘ayahuasca’ from quechua is ‘the vine of the dead’ or ‘the vine
of the soul’), has also been linked to themes of death and dying
(Shanon, 2005) as have psychedelics in general (Millière, 2017),
e.g., with the psychology of psychedelic-induced ‘ego-death’ being
likened to that of actual death (Leary et al., 2008).
Both the psychedelic experience and NDEs appear to be
sensitive to contextual factors such as prior psychological
traits and state (‘set’), the environment (‘setting’) in which
the experience unfolds (Metzner et al., 1965; Studerus et al.,
2012) – plus the broader cultural context in which they are
embedded (Wallace, 1959; Hartogsohn, 2017; Carhart-Harris
et al., 2018). For example, controlled research has found that
certain personality traits, e.g., ‘absorption’ and ‘neuroticism’ can
predict the intensity and quality of a psychedelic experience
(Studerus et al., 2012; Carhart-Harris et al., 2015, 2018;
Carbonaro et al., 2016; Barrett et al., 2017) while readiness
to ‘let go’ and quality of the environment also seems to be
predictive of response (Carhart-Harris et al., 2018). In a similar
fashion, the prevalence and nature of NDEs appear to be sensitive
to environmental, demographic and personality variables, such
as etiology and prognosis of the NDE, age, absorption and
a propensity to report paranormal experiences (Kohr, 1983;
Greyson, 2003). Cultural factors are presumed to influence the
psychedelic experience (Carhart-Harris et al., 2018) and have
been found to influence the content of NDEs, (Kellehear, 1993;
Kellehear et al., 1994).
The near-death experience has been associated with long-
term positive changes in psychological well-being and related
outcomes; more specifically, greater concern for others,
reductions in distress associated with the prospect of dying,
increased appreciation for nature, reduced interest in social
status and possessions, as well as increased self-worth have all
been observed and/or described post NDEs (Noyes, 1980; Ring,
1980; Groth-Marnat and Summers, 1998). Relatedly, recent
results from studies with psychedelic compounds have shown
similar long-term positive changes. For example, reduced death
anxiety (Grob et al., 2011; Gasser et al., 2015; Griffiths et al.,
2016; Ross et al., 2016), pro-ecological behavior (Forstmann and
Sagioglou, 2017; Nour et al., 2017) and nature relatedness (Lyons
and Carhart-Harris, 2018), significant clinical improvements
in depressed patients (Osório et al., 2015; Carhart-Harris et al.,
2016; Palhano-Fontes et al., 2018) and recovering addicts
(Johnson et al., 2014; Bogenschutz et al., 2015; Bogenschutz
and Johnson, 2016) and lasting improvements in psychological
well-being in healthy populations (Griffiths et al., 2011; Carhart-
Harris et al., 2017) have all been observed. Thus, overlap between
near-death and psychedelic experiences may extend beyond the
acute experience into longer-term psychological changes.
While the subjective effects of DMT have been researched
in the past (Strassman et al., 1994; Gouzoulis-Mayfrank et al.,
2005), they have tended to be collapsed into broad categories
or dimensions of experience (e.g., visual, somatic and emotional
effects) as determined by standard ‘altered states of consciousness’
rating scales (Strassman et al., 1994; Studerus et al., 2010).
The degree to which DMT specifically induces near-death type
experiences has never been directly measured, however.
This current within-subjects, placebo-controlled study aimed
to directly measure the extent to which intravenous DMT given
to healthy volunteers in a laboratory setting could induce a near-
dear type experience as determined by a standard NDE rating
scale (Greyson, 1983). Importantly, we also aimed to address
how these experiences compared with a sample of individuals
who claim to have had ‘actual’ near-death experiences. To our
knowledge, this is the first time that the relationship between
DMT experiences and (non-drug-induced) NDEs has ever been
formally addressed.
We hypothesized that DMT would induce near-death type
experiences of an equivalent intensity to those seen previously
in the context of ‘actual’ NDEs, and to a significantly greater
extent than in the placebo condition. Based on aforementioned
work on NDEs, we also hypothesized that age, personality and




Thirteen healthy volunteers participants (6 female, 7 male, mean
age: 34.4, SD: 9.1 years) participated in a fixed-order, placebo-
controlled, single blind study, approved by the National Research
Ethics Service (NRES) Committee London – Brent and the
Health Research Authority (HRA). This study was carried out in
accordance with the recommendations of Good Clinical Practice
guidelines, Declaration of Helsinki ethical standards and the
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NHS Research Governance framework. All subjects gave written
informed consent in accordance with the Declaration of Helsinki.
The study was sponsored and approved by Imperial College
London’s Joint Research and Compliance Office (JRCO) and the
National Institute for Health Research/Wellcome Trust Imperial
Clinical Research Facility gave site-specific approval for the study.
The research was conducted under a Home Office license for
research with Schedule 1 drugs. Study procedures consisted of
screening and 2 dosing sessions, separated by 1 week.
Screening
Participants were recruited via word-of-mouth and received an
information sheet detailing all study procedures prior to the
screening visits. Informed consent was obtained before screening,
which consisted of routine physical tests (routine blood tests,
electrocardiogram, blood pressure, heart rate, neurological
examination) a psychiatric interview and examination. The main
exclusion criteria were: an absence of experience with a classic
psychedelic drug (e.g., LSD, psilocybin, DMT, ayahuasca), current
or previously diagnosed psychiatric illness, immediate family
history of psychotic disorder, excessive use of alcohol (>40
weekly units), blood or needle phobia and a significant medical
condition rendering volunteers unsuitable for participation (e.g.,
diabetes, heart condition). Tests for drug abuse and pregnancy
(when applicable) were performed on screening and study
days and participants were required to abstain from using
psychoactive drugs at least 7 days prior to study participation.
Following screening, participants were enrolled for 2 dosing
sessions in which placebo and DMT were administered.
Questionnaires were completed electronically prior to the dosing
sessions – which served as baseline correlation measures.
Following each dosing sessions, participants completed
questionnaires enquiring about subjective experiences during the
DMT and placebo sessions. The Greyson NDE scale (Greyson,
1983) served as the primary outcome measure.
Study Procedures and Participants
Both dosing sessions took place at the National Institute of
Health Research (NIHR) Imperial Clinical Research Facility
(CRF). Participants rested in reclined position in a dimly lit
room, while low volume music was played in the background
in order to promote calm during the session (Johnson et al.,
2008). Electroencephalogram (EEG) recordings took place before
and following administration of DMT and placebo (the relevant
findings concerning EEG results will be reported elsewhere).
Participants received one of four doses of DMT fumarate
(three volunteers received 7 mg, four received 14 mg, one
received 18 mg and five received 20 mg) via intravenous route
in a 2 ml sterile solution over 30 s, followed by a 5 ml saline flush
lasting 15 s. Placebo consisted of a 2 ml sterile saline solution,
which followed the same procedure (Strassman and Qualls,
1994). During the first dosing session, all participants received
placebo, and 1 week later, DMT. Participants were unaware of
the order in which placebo and DMT were administered but
the research team was (i.e., single-blind study design). The order
was fixed in this way to promote safety by developing familiarity
with the research team and environment prior to receiving DMT,
and to avoid potential carry over effects from receiving DMT
first (particularly as the experience is associated with lasting
psychological effects – see section “Introduction”).
Participants reported feeling the subjective effects of DMT
immediately after the 30 s injection or during the flush
which came soon after it. Effects peaked at 2–3 min and
gradually subsided, with only residual effects felt 20 min post
administration. Volunteers were discharged to go home by a
study psychiatrist at least 1 h after administration and once all
study procedures were completed. Participants were asked to
message a member of the research team in order to confirm
their safe return and well-being. To ensure safety, each volunteer
was supervised by two researchers and the study physician
throughout the dosing session.
Main Outcomes and Measures
Acute Outcomes
In order to determine the degree to which DMT induces near-
death type experiences, the Near-Death Experience scale (NDE
scale; Greyson, 1983) was completed retrospectively once the
effects of DMT and placebo had subsided. This is the most widely
used scale for NDEs; it was first constructed from a questionnaire
based on a sample of 67 participants who had undergone 73
NDEs in total (Greyson, 1983). The NDE scale consists of 16
items, resulting in a total score representing the global intensity of
the experience as well as scores for four subscales: (1) Cognitive,
(2) Affective, (3) Transcendental, and (4) Paranormal. A total
score higher or equal to 7 is considered the threshold for a NDE
(Greyson, 1983).
The overlap between drug-induced NDEs and other relevant
psychological phenomena associated with psychedelic drugs was
also addressed. Two additional measures were included for this
purpose, namely: The Ego Dissolution Inventory (EDI) (Nour
et al., 2016) and the Mystical Experiences Questionnaire (MEQ)
(Maclean et al., 2013). The EDI contains 8 items and a mean score
on all 8 is calculated for a single EDI factor. The MEQ contains 30
items and yields a total score consisting of the average of all items
as well as four subscales: Mystical, Positive Mood, Transcendence
of Time and Space and Ineffability (Maclean et al., 2013; Barrett
et al., 2015).
Additional Measures
Correlations with personality trait absorption, delusional
thinking and age
Questionnaires completed at baseline (before study visits) were
used to assess the relationship between personality, suggestibility,
delusional thinking and age with the magnitude of the NDE
scores. Previous research has identified that the personality trait
absorption and reports of so-called ‘paranormal’ phenomena
(e.g., telepathic communication, out-of-body experiences) are
positively correlated with the NDE scores, while age is negatively
correlated with NDE scores (Kohr, 1983; Greyson, 2003). Because
reports of paranormal experiences have been associated with
magical ideation and schizotypy (Brugger and Taylor, 2003) we
used the Peters’ Delusion Inventory (PDI) (Peters et al., 2004)
to establish the relationship between this construct and NDE
scores. The PDI is a measure of delusional thinking in the
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general population and contains items related to paranormal
phenomena (e.g., belief in telepathy, witchcraft, and voodoo) as
well as strength of belief and level of distress associated with these
(Peters et al., 2004).
Participants were also asked to complete the modified
version of the Tellegen Aborption Questionnaire (MODTAS)
(Tellegen and Atkinson, 1974). Pearson-product moment
correlations were used to test for relationships between the
relevant variables and main outcomes (i.e., the relationship
between absorption, delusional thinking and age with
NDE scores was analyzed). In order to adhere to statistical
principles, one-tailed analyses were performed in cases in
which there were clear, evidence-informed hypotheses about
the direction of correlations, otherwise two-tailed tests were
performed.
Comparison to ‘actual’ NDE group
In order to address the degree of overlap between our results
and the features typically reported by people who have reported
‘actual’ NDEs, we conducted a separate comparison with gender
and age matched sample of individuals who had completed the
NDE scale (and scored above the established cutoff for an NDE)
from a few months to 15 years (mean time = 7 years, SD = 6 years)
after experiencing a life-threatening episode. This sample was
defined as the NDE group (7 female, 6 male, mean age = 36.62,
SD = 7.65). NDE experiencers were recruited via the Coma
Science Group (GIGA-Consciousness, University and University
Hospital of Liège, Belgium) and the International Associations for
Near-Death Studies (IANDS France and Flanders). Participants
were mailed a questionnaire that included items about socio-
demographic (gender, age at interview) and clinical (time since
NDE) characteristics. They were then asked to respond to the
Greyson NDE scale (Greyson, 1983).
Statistical Analysis
To compare the acute effects of DMT with those of placebo,
repeated measures Analysis of Variance (ANOVA) were
performed separately on data from the NDE scale and the
MEQ, using condition (DMT vs. placebo) and questionnaire
subscales as the factors of interest. Post hoc paired t-tests were
then performed to compare DMT vs. placebo. In order to dissect
the relationship between the DMT and near-death experiences,
each item of the NDE scale was also subjected to paired t-tests
(DMT vs. placebo). The comparison between the DMT state and
‘actual’ near-death experiences was made by conducting paired
t-tests for each NDE scale item, as well as its subscales and total
score.
Overlap between MEQ and NDE scale scores was assessed via
Pearson-Product Moment Correlation on the main score of the
difference between DMT and placebo for both scales, and the
same procedure was performed between the EDI and the NDE
scale. Independent correlation analyses were performed using the
main score of the NDE (DMT-placebo) and each of the MEQ
sub-factors in order to determine which of the MEQ sub-factors
shows the strongest association with the total NDE scale scores.
Effect sizes were calculated using Cohen’s d for all paired
t-tests. Separate Pearson-Product Moment Correlations were
performed using each of the variables collected at baseline
vs. the total NDE score. All analyses that involved less than
15 comparisons used Bonferroni-correction for multiple
comparisons, while those equal/above 15 comparisons used
False-Discovery Rate (FDR) correction. All t-tests were
performed under two-tailed analyses.
RESULTS
DMT Induces Near-Death Type
Experiences
All participants scored above the conventional cutoff (above or
equal to 7) for a (DMT-induced) near-death (type) experience
(Greyson, 1983). One of the 13 participants had a total score
of 7 following placebo. The Analysis of Variance revealed
a significant main effect of condition [F(1,12) = 118.95,
p = 1.39e−7], a main effect of NDE subscale [F(4,48) = 59.36,
p = 5.39e−18] and an interaction between condition and
NDE subscale [F(3,36) = 11.92, p = 1.4e−5]. Post hoc t-tests
revealed all NDE subscales and the total NDE score to
be significantly increased under DMT compared to placebo
(p < 0.01 Bonferroni corrected) and the comparison of the total
score was significantly higher for DMT compared to placebo
(t = 10.91, df = 12, p = 1.39e−7, Cohen’s d = 3.09). Paired
t-tests on each of the 16 items comprising the NDE scale were
performed in order to assess the specific phenomenological
features of the DMT experience. Fifteen of the 16 items were
scored higher under DMT than placebo and 10 of these
reached statistical significance after correction (p < 0.01 FDR-
corrected) (Figure 1). These results show that near-death
experience phenomena were significantly enhanced following
DMT administration.
Ego-Dissolution Inventory (EDI) and
Mystical Experience Questionnaire
(MEQ)
A paired comparison using the EDI revealed highly significant
larger total scores for DMT compared to placebo (T = 6.98,
df = 12, p = 1.47e−5, Cohen’s d = 2.67). Analysis on the Mystical
Experience Questionnaire (MEQ) (Maclean et al., 2013) revealed
a main effect of condition [F(1,12) = 133.27, p = 7.43e−8], a main
effect of MEQ sub-scale or factor [F(3,36) = 4.66, p = 0.007] and a
condition∗factor interaction [F(3,36) = 3.35, p = 0.03]. Post hoc
t-tests revealed that all MEQ factors were significantly higher
following DMT compared to placebo (p < 0.001) and the total
score was also significantly increased under DMT vs. placebo
(t = 10.11, df = 12, p = 3.17e−7, Cohen’s d = 3.81).
The difference between DMT and placebo scores for the
NDE scale, EDI and MEQ were used for correlation analysis.
These analyses revealed a significant correlation for both the EDI
(r = 0.69, r2 = 0.47, p = 0.0096) and MEQ (r = 0.90, r2 = 0.81,
p = 2.60e−5) with the NDE scale (Figure 2). Independent Pearson
Product-Moment correlation analyses were performed using
each of the different MEQ factors separately against the NDE
total score. A significant relationship was revealed between the
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FIGURE 1 | Near-Death Experience (NDE) scale results for DMT vs. placebo. Significantly larger scores for DMT versus placebo were found for (A) 10 out of 16
items of the NDE scale; (B) all NDE subscales; and (C) the NDE scale total (the dotted red line corresponds to the conventional threshold for determining an NDE)
(∗p < 0.05, ∗∗p < 0.01, corrected for multiple comparisons).
Mystical (r = 0.9, r2 = 0.81, p< 0.001) and Transcendence of Time
and Space (r = 0.72, r2 = 0.51, p = 0.006) factors and the NDE
score, while Positive Mood (r = 0.67, r2 = 0.45, p = 0.013) and
Ineffability (r = 0.63, r2 = 0.40, p = 0.021) did not survive multiple-
comparison correction (0.05/4 = 0.0125). Overall these results
indicate a high overlap between near-death type experiences,
ego-dissolution and mystical-type experiences induced by DMT.
With specific regards to the mystical experience, MEQ factors
Mystical and Transcendence of Time and Space were most
strongly associated with the DMT-induced near-death type
experiences.
Correlations With Personality, Delusional
Ideation and Age
The personality trait absorption has been associated with NDEs
in patient populations (Twemlow and Gabbard, 1984), therefore
a Pearson Product-Moment Correlation analysis was performed
using the scores of Tellegen Absorption Scale (MODTAS)
and NDE questionnaire. Alleged ‘paranormal’ experiences have
also been associated with higher NDE scores (Kohr, 1983;
Greyson, 2003) and delusional thinking (measured through
the PDI) and younger age have also been shown to correlate
with NDE scores. Here, correlation analysis revealed a positive
relationship between baseline PDI scores and NDE scores
after DMT (r = 0.61, r2 = 0.37, p = 0.013, one-tailed).
Similarly, baseline MODTAS absorption scores showed the
same relationship (r = 0.57, r2 = 0.33, p = 0.02, one-tailed);
however, this did not survive multiple comparison correction
(0.05/4 = 0.0125). Performing the same analysis after excluding
an outlier revealed a trend relationship between NDE scale
and MODTAS scores (r = 0.45, r2 = 0.21, p = 0.07, one-
tailed) but no significant relationship between the PDI and
the NDE scale (r = 0.19, r2 = 0.04, p = 0.28, one-tailed)
(Figure 3), nor between age and NDE (r = −0.36, r2 = 0.13,
p = 0.16).
Comparison to ‘Actual’ Near-Death
Experiences
A separate analysis was performed using a gender/age matched
sample of volunteers who reported having gone through an
‘actual’ NDE. Participants were selected based on scores above a
standard cut-off on the NDE scale of 7 points (Greyson, 1983).
Table 1 and Figure 4 displays the results from separate t-tests
performed on each item, subscales and total score. Overall the
results show that the total NDE scores induced by DMT are
comparable to those given by the ‘actual’ NDE group (t = 1.85,
df = 12, p = 0.089, Cohen’s d = 0.49).
All of the subscales ratings were also comparable between
NDE and DMT conditions. The only feature showing a significant
difference was the item “Did you come to a border or point of no
return” – which was scored higher by the NDE group compared
to the DMT condition (t = 2.74, df = 12, p = 0.018 – uncorrected,
Cohen’s d = 1.07); however, this result did not survive correction
for multiple comparisons (see Table 1 for differences on specific
items of the NDE scale). Overall, comparable NDE scores can be
seen for the ‘actual’ NDE group and the DMT condition.
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FIGURE 2 | Ego-Dissolution Inventory (EDI) and Mystical Experiences Questionnaire (MEQ) scores and relationship with Near-Death Experience (NDE) scale scores.
Significantly higher scores were found for DMT compared to placebo for (A) EDI and (C) MEQ scores. A highly significantly positive correlation was found between
the NDE scale and (B) EDI and (D) MEQ scores following DMT administration.
FIGURE 3 | Association between the NDE scale scores following DMT administration and baseline measures of (A) delusional beliefs (PDI) and (B) Absorption
scores (MODTAS). The transparent red line shows the slope of the r-value discarding the outlier.
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DISCUSSION
This study sought to examine the degree to which features
commonly reported in NDEs are elicited by the potent
serotonergic psychedelic DMT in a placebo-controlled study.
Results revealed that all 13 participants scored above the standard
threshold for an NDE in relation to their DMT experiences
(Greyson, 1983) and 15 of the 16 NDE items were rated
significantly higher under DMT compared to placebo, with 10
of these reaching statistical significance after multiple testing
correction.
Especially strong overlap was seen between DMT-induced
near-death type experiences and mystical-type experiences
(MEQ, Griffiths et al., 2006, 2016; Kometer et al., 2015), with the
Mystical factor of the MEQ (which contains items such as “sense
of being at a spiritual height” and “experience of oneness or unity
with objects and/or persons in your surroundings”) showing the
highest relationship with NDE total scores. Intriguingly, DMT-
induced NDE scores were significantly correlated with baseline-
measured delusional thinking. Perhaps most interesting of all
however, when these DMT data were compared with those from
a matched sample of ‘actual’ NDEs, a comparable profile was
evident, with few discernable differences between the experiences
of the actual NDE cases and those induced by DMT. Taken
together, these results reveal a striking similarity between the
phenomenology of NDEs and experiences induced by the classic
serotonergic psychedelic, DMT.
As reported above, 10 of 16 NDE items were scored
significantly higher under DMT than placebo. Items that
did not survive multiple comparison correction (experiences
of extrasensory perception, life-review, precognition of future
events, increased speed of thoughts and seeing deceased
people/relatives) are also items that are less commonly endorsed
in ‘actual’ NDEs (Schwaninger et al., 2002; Greyson, 2003;
Vanhaudenhuyse et al., 2009). The Affective subscale of the NDE
scale was scored particularly highly under DMT, and emotion
is also a prominent feature of actual NDEs (Greyson, 1983,
2003; Schwaninger et al., 2002; Martial et al., 2017). Subtle
differences that were apparent between the DMT condition
and NDEs (e.g., the experience of entering an unearthly realm
was enhanced for DMT vs. actual NDEs, whereas coming
to a point of no return was scored higher in actual NDEs
compared with the DMT experience) may be explainable by
the very different contexts in which these experiences occur
(e.g., DMT was given here with prior screening, psychological
preparation and consent in a safe laboratory setting vs. an NDE
occuring during an illness or unexpected accident) as much as
differences due to the inducers themselves or their associated
neurobiologies.
It is important to acknowledge that the phenomenology of
NDEs is still a matter of some investigation. Initially, 15 NDE
features were proposed when the term was first coined – based on
interviews with more than 50 NDE ‘experiencers’ (Moody, 1975);
after this, 5 core features were identified via structured interviews
(Ring, 1980), and subsequently Greyson (1983) identified 16
features using statistical methods in a study comprising 73
different NDEs.
It has recently been shown that the temporal sequence of
events unfolding during an NDE is highly variable between
people and no prototypical sequence was identifiable in a
TABLE 1 | Comparison of NDE scale features between ‘actual’ NDEs and following DMT administration (matched samples) (∗p < 0.05 uncorrected).
NDE scale mean scores (SD) Effect size (Cohen’s d)
Items NDE DMT NDE vs. DMT
Cognitive subscale 3.77 (2.24) 2.15 (1.77) 0.80
Did time seem to speed up or slow down? 1.54 (0.78) 1.15 (0.80) 0.49
Were your thoughts speeded up? 0.69 (0.85) 0.46 (0.66) 0.30
Did scenes from your past come back to you? 0.54 (0.88) 0.15 (0.38) 0.57
Did you suddenly seem to understand everything? 1.00 (0.82) 0.38 (0.77) 0.78
Affective subscale 4.46 (2.57) 4.85 (1.63) −0.18)
Did you have a feeling of peace or pleasantness? 1.38 (0.77) 1.46 (0.52) −0.12
Did you have a feeling of joy? 1.00 (0.82) 1.08 (0.49) −0.11
Did you feel a sense of harmony or unity with the universe? 1.08 (0.76) 1.31 (0.95) 0.00
Did you see, or feel surrounded by, a brilliant light? 1.00 (0.71) 1.00 (0.91) 0.00
‘Paranormal’ subscale 3.62 (1.89) 2.85 (1.52) 0.36
Were your senses more vivid than usual? 1.08 (0.76) 1.38 (0.65) −0.44
Did you seem to be aware of things going on elsewhere, as if by extrasensory perception (ESP)? 0.38 (0.77) 0.15 (0.38) 0.38
Did scenes from the future come to you? 0.62 (0.77) 0.23 (0.60) 0.56
Did you feel separated from your body? 1.54 (0.78) 1.08 (0.76) 0.60
Transcendental subscale 4.15 (2.30) 3.46 (1.66) 0.34
Did you seem to enter some other, unearthly world? 1.31 (0.85) 1.69 (0.48) −0.55
Did you seem to encounter a mystical being or presence, or hear an unidentifiable voice? 0.92 (0.95) 1.08 (0.95) −0.17
Did you see deceased or religious spirits? 0.92 (1.04) 0.46 (0.78) 0.50
Did you come to a border or point of no return? 1.00 (0.82) 0.23 (0.60) 1.07∗
Total 16 (6.28) 13.31 (4.55) 0.49
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FIGURE 4 | Comparison of near-death experience (NDE) features in ‘actual’ NDEs and the DMT experience using a standard NDE scale (Greyson, 1983). No
significant differences were found between DMT administration and ‘actual’ NDEs for (A) 15 out of 16 NDE scale items; (B) all NDE subscales; and (C) the NDE
scale total score (The dotted red line corresponds to the threshold for an NDE). (∗p < 0.05 uncorrected).
sample of 154 participants, although four main dimensions were
relatively consistent, namely: ‘out-of-body experiences,’ ‘seeing
a bright light,’ ‘encountering spirits/people,’ and a ‘feeling of
peace’ (Martial et al., 2017). The potential heterogeneity of
NDEs cautions us to consider how intra and inter-individual
variables, cultural characteristics and the environmental and
psychological context in which they take place may influence
the content of experiences as well as whether and how they are
reported.
Personality has previously been associated with response to
psychedelics (Studerus et al., 2012; Hartogsohn, 2016; Barrett
et al., 2017). For example, trait ‘absorption’ has been shown to
be predictive of sensitivity to psychedelics (Studerus et al., 2012),
and the same has also been shown in relation to the intensity
of ‘actual’ NDEs (Twemlow and Gabbard, 1984). Absorption has
been linked to a serotonin 2A receptor polymorphism associated
with greater signaling (Ott et al., 2005); thus, it is intriguing
to consider whether abnormal serotonergic functioning may
contribute to both psychedelic and NDEs (Carhart-Harris and
Nutt, 2017). Here, we saw a trend toward absorption predicting
DMT-induced NDE but this relationship did not quite reach
statistical significance, perhaps due to insufficient statistical
power or that the use of different doses might have masked this
effect.
It has been previously shown that the reported intensity
of NDEs is associated with a tendency to report so-called
‘paranormal’ experiences (Kohr, 1983; Greyson, 2003). Our
results show that baseline delusional thinking (as measured by
Peters’ Delusion Inventory), was strongly associated with NDE
scores. One possible interpretation of this is that – like people
with paranormal beliefs – people with higher than average
delusional thinking are more emphatic in their endorsement
of NDE phenomena as they view it as less at odds with
their pre-existing belief systems and perhaps even see it as
‘evidence’ for metaphysical and/or mystical beliefs which they
already endorse. Recent findings (Martial et al., 2018) have
found a strong relationship between ‘fantasy proneness’ and NDE
phenomena reported by individuals in situations in which there
has been no genuine threat to their lives (e.g., in meditative
states or under intense psychological distress). These results
support the view that individuals’ traits and beliefs might
strongly influence the appearance of such phenomena in a
range of different contexts, which could account for our current
findings.
Relatedly, we found a strong relationship between scores of
DMT-induced near-death type and mystical-type experiences.
More specifically, we found a strong association between the total
NDE score and the MEQ factors ‘Mystical’ and ‘Transcendence
of Time and Space.’ The Mystical factor corresponds to items
pertaining to an experience of unity or continuity between
self/ego and the external world (known elsewhere as ‘dissolved
ego-boundaries’- Nour et al., 2016), an intuitive feeling of so-
called ‘sacredness’, and the experience of gaining insights into
‘ultimate truths’. The factor Transcendence of Time and Space
corresponds to experiences of loss of one’s usual spatial and
temporal orientation and a sense of vastness, continuity and
eternity (Pahnke and Richards, 1970; Maclean et al., 2013).
The strong overlap between these facets of mystical-type and
NDEs may be due to similar items featuring in both scales
(e.g., items pertaining changes in time perception, experiences
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of unity, feelings of peace) which could be seen as evidence
of their strong phenomenological overlap – but there are also
some items that are distinct between the scales, e.g., feelings of
being separated from one’s one body, encountering beings or
presences.
Recent work has consistently shown that the occurrence of
mystical-type experiences is predictive of long-term therapeutic
benefit from psychedelics (Maclean et al., 2011; Garcia-Romeu
et al., 2014; Griffiths et al., 2016; Carhart-Harris et al., 2017,
2018; Roseman et al., 2018) and similar mechanisms may be
at play in relation to improved mental well-being post NDE
(Moody, 1975; Noyes, 1980; Ring, 1980; Groth-Marnat and
Summers, 1998). It is pertinent to ask therefore, what common
features shared between these states may be responsible for
mediating the apparent long-term psychological benefits that
follow them. Evidence suggests that that the experience of
unity – which some have claimed is an inevitable counterpart
to ego-dissolution (Nour et al., 2016) – may be the core
component binding them both. The so-called ‘unitive experience’
was originally identified as the core component of the mystical
experience by its most influential scholar, Walter Stace (Stace,
1960) and it is also recognized in descriptions of the ‘peak
experience’ – an overtly secular equivalent of the so-called
‘mystical experience’ introduced by Maslow (1959), as well as
the ‘oceanic feeling’ coined by Romain Rolland in conversation
with Sigmund Freud, who believed the feeling to be regressive,
recapitulating the state of consciousness inhabited by infants
prior to the development of the ego (Freud, 1920). It is possible
that complete ego-dissolution and the parallel unitive experience
that accompanies it may be the common factor that can bridge
between these different states and is also responsible for the
longer-term psychological benefits associated with them. Another
recent thought, is that a return of the brain to ‘criticality’
(Atasoy et al., 2017), albeit temporarily, may offer a reminder
of one’s closeness with nature (Carhart-Harris, 2018) and so
what is left afterwards is as much an epistemic ‘reminder’ as
anything else.
Detailed interviewing techniques could serve to improve our
characterization of the phenomenology of both the DMT and
NDE states (Petitmengin, 2006; Petitmengin and Lachaux, 2013),
and future studies of the psychedelic state could benefit from
adopting a more dynamic sampling approach, i.e., by attempting
to detail the temporal unfolding of the experience – as has been
done recently in the context of NDEs (Martial et al., 2017) and
elsewhere in relation to stream of consciousness (Smallwood and
Schooler, 2015). We predict that improved ‘capture’ of certain
transient experiences within a broader psychedelic experience
may help finesse our understanding of its psychology and
associated neurobiology.
Rudimentary neurobiological models of the NDE have existed
for almost 30 years, and have tended to lay emphasis on abnormal
serotonergic and medial temporal lobe activity (Morse et al.,
1989; Saavedra-Aguilar and Gómez-Jeria, 1989; Britton and
Bootzin, 2004) – consistent with the predominantly serotonergic
pharmacology of classic psychedelics (Nichols, 2016) as well
as findings from fMRI (Tagliazucchi et al., 2014; Carhart-
harris et al., 2016) and depth EEG recordings of human brain
activity under psychedelics which implicate the medial temporal
lobes (Carhart-Harris, 2007; Carhart-Harris and Nutt, 2014).
Given strong associations between the temporal lobes and
more specifically, medial temporal lobe structures, and unusual
psychological experiences such as those featuring within NDEs
(Carhart-Harris, 2007), we predict that the medial temporal
regions may be implicated in some of the content and emotion-
rich epochs that arise within the psychedelic state, such as
complex imagery, entity encounters, and vivid autobiographical
recollections. The relinquishment of top-down cortical control
over temporal lobe activity may be an important component
of this mechanism (Alonso et al., 2015; Kaelen et al., 2016;
Timmermann et al., 2017).
Limitations
It is important to acknowledge this study’s limitations. The dose
of DMT was not uniform for all participants due to this study
being part of a dose-finding pre-study ahead of a larger EEG-
fMRI study with DMT. The lower doses of DMT may have
actually depreciated the true strength of the similarities between
the DMT state and the near-death experience therefore, and we
should also acknowledge that individuals included within the
‘actual’ NDE sample had to give NDE-scale scores above a specific
threshold, whereas this pre-requisite wasn’t stipulated for our
DMT sample.
Another limitation is that we cannot discount the influence
of order effects as placebo sessions were always performed
first (to avoid carryover and promote comfort for the DMT
session) and thus, exposure to the NDE scale post placebo may
have primed participants to experience NDE-like phenomena
ahead of their DMT sessions – although this seems unlikely
given the volume of other measures and time between sessions.
The positive scores on the NDE scale might also reflect a
general tendency to endorse ‘anything unusual’ in relation to
the psychedelic experience, particularly as psychedelics have
been shown to promote suggestibility (Carhart-Harris et al.,
2015). Contradicting this explanation, however: (1) participants’
mental state had largely returned to baseline by the time
they completed the NDE scale, (2) responses to the different
dimensions of the NDE scale resembled those seen in relation
to actual NDEs, and (3) an open interview performed post
experience (but before questionnaires were completed) promoted
careful reflection on the details of the DMT state. That one
participant scored on the threshold for an NDE in the placebo
session suggests that the NDE scale may have a somewhat
liberal threshold for determining NDEs – and thus may warrant
revision.
As both psychedelics and the NDE phenomena appear to
be strongly influenced by contextual factors (Kellehear et al.,
1994; Carhart-Harris et al., 2018), it could be argued that
significant differences may exist regarding phenomenological
features between both experiences. Nonetheless, considering
the strong overlap on the items of the NDE scale, the
study of such differences might require the use of other
methods addressing nuances not explored here (e.g., the use
of questionnaires addressing contextual factors and qualitative
studies).
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We should also consider that although the study of the
phenomenology of NDEs and psychedelic experiences may
inform on each other in a reciprocal way, using one psychological
phenomenon to model another, particularly if they are as
abstract as the near-death and psychedelic experiences are,
these may be fraught with problems (see Langlitz, 2017
for a detailed reflection on psychedelics as models of other
mental and psychiatric phenomena). For this reason, better
understanding their (presumed) shared neurobiology may
provide the necessary bedrock to ground the science of these
fascinating states.
CONCLUSION
This study aimed to examine potential overlap between
the phenomenology of NDEs and those associated with
the potent serotonergic psychedelic DMT. Results revealed
an intriguingly strong overlap between specific and broad
features of these states, with DMT participants scoring high
on a standard measure of NDEs and in a comparable
way to people reporting bona fide NDEs, with only subtle
differences that might relate more to obvious contextual
differences than anything to do with the specific inducers
themselves.
Indeed, these present results suggest that certain contextual
factors (e.g., delusional thinking and personality trait absorption)
can significantly mediate both the intensity and quality of the
DMT-induced NDE-like experiences, advancing the notion that –
as with the psychedelic experience more broadly (Carhart-
Harris et al., 2018) – the intensity and content of NDEs
are context-dependent. This study’s findings warrant further
investigation to address the putatively strong overlap between
the phenomenology and neurobiology of DMT (and other
psychedelic) experiences and ‘actual’ near-death experiences,
particular given some of the scientifically problematic yet
influential claims that have been made about NDEs (Alexander,
2012).
Better understanding of both the psychology and
neurobiology of dying (Borjigin et al., 2013) – e.g., by using
psychedelics to model it – may have implications for how we
view this most inevitable and universal phenomenon, potentially
promoting a greater familiarity with and healthy acceptance of it.
‘By meditating on death, we paradoxically become conscious of
life. How extraordinary it is to be here at all. Awareness of death
can jolt us awake to the sensuality of existence.’ (Batchelor, 1998).
AUTHOR CONTRIBUTIONS
CT designed and conducted the research, analyzed the data,
and wrote the paper. LR and LW conducted the research. DE
overlooked medical and health standards for the research. CM,
HC, and SL contributed the data from the NDE group. DN
sanctioned the research. RC-H designed the research and wrote
the paper.
FUNDING
CT was supported by Comisión Nacional de Investigación
Científica y Tecnológica de Chile (CONICYT). RC-H was
supported by the Alex Mosley charitable trust. This work was
supported by the Bial Foundation and the Beckley Foundation.
ACKNOWLEDGMENTS
The authors would like to thank all study participants, as well
as Samuel Turton, Matthew Nour, Camilla Day, and James
Rucker for providing medical cover during study procedures.
This research was conducted at the National Institute of Health
Research (NIHR) Imperial Clinical Research Facility (CRF). The
authors would also like to thank Rick Strassman and Andrew
Gallimore for providing advice during the development of early
versions of the study protocol. This work received support from
Amanda Feilding and the Beckley Foundation (the study was
conducted as part of the Beckley-Imperial Research Program).
REFERENCES
Alexander, E. (2012). Proof of Heaven: A Neurosurgeon’s Journey into the Afterlife.
London: Piatkus.
Alonso, F. J., Romero, S., Mañanas, M. A., and Riba, J. (2015). Serotonergic
psychedelics temporarily modify information transfer in humans. Int. J.
Neuropsychopharmacol. 18, 1–9. doi: 10.1093/ijnp/pyv039
Atasoy, S., Roseman, L., Kaelen, M., Kringelbach, M. L., Deco, G., and Carhart-
Harris, R. L. (2017). Connectome-harmonic decomposition of human brain
activity reveals dynamical repertoire re-organization under LSD. Sci. Rep.
7:17661. doi: 10.1038/s41598-017-17546-0
Barrett, F. S., Johnson, M. W., and Griffiths, R. R. (2015). Validation of
the revised mystical experience questionnaire in experimental sessions with
psilocybin. J. Psychopharmacol. 29, 1182–1190. doi: 10.1177/02698811156
09019
Barrett, F. S., Johnson, M. W., and Griffiths, R. R. (2017). Neuroticism is associated
with challenging experiences with psilocybin mushrooms. Pers. Individ. Dif.
117, 155–160. doi: 10.1016/j.paid.2017.06.004
Batchelor, S. (1998). Buddhism Without Beliefs: A Contemporary Guide to
Awakening. London: Bloomsbury Publishing PLC.
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa,
P. C. R., and Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol
dependence: a proof-of-concept study. J. Psychopharmacol. 29, 289–299. doi:
10.1177/0269881114565144
Bogenschutz, M. P., and Johnson, M. W. (2016). Classic hallucinogens in the
treatment of addictions. Prog. NeuroPsychopharmacol. Biol. Psychiatry 64,
250–258. doi: 10.1016/j.pnpbp.2015.03.002
Borjigin, J., Lee, U., Liu, T., Pal, D., Huff, S., Klarr, D., et al. (2013). Surge of
neurophysiological coherence and connectivity in the dying brain. Proc. Natl.
Acad. Sci. U.S.A. 110, 14432–14437. doi: 10.1073/pnas.1308285110
Britton, W. B., and Bootzin, R. R. (2004). Near-death experiences and the temporal
lobe. Psychol. Sci. 15, 254–258. doi: 10.1111/j.0956-7976.2004.00661.x
Brugger, P., and Taylor, K. I. (2003). ESP: extrasensory Perception or Effect of
Subjective Probability? J. Conscious. Stud. 10, 221–246.
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R.,
Johnson, M. W., et al. (2016). Survey study of challenging experiences
Frontiers in Psychology | www.frontiersin.org 10 August 2018 | Volume 9 | Article 1424
fpsyg-09-01424 August 13, 2018 Time: 9:22 # 11
Timmermann et al. DMT and Near-Death Experiences
after ingesting psilocybin mushrooms: acute and enduring positive and
negative consequences. J. Psychopharmacol. 30, 1268–1278. doi: 10.1177/
0269881116662634
Carhart-Harris, R. (2007). Waves of the unconscious: the neurophysiology of
dreamlike phenomena and its implications for the psychodynamic model of
the mind. Neuropsychoanalysis 9, 183–211. doi: 10.1080/15294145.2007.1077
3557
Carhart-Harris, R. (2018). The entropic brain - Revisited. Neuropharmacology
doi: 10.1016/j.neuropharm.2018.03.010 [Epub ahead of print].
Carhart-Harris, R., and Nutt, D. (2014). Was it a vision or a waking dream? Front.
Psychol. 5:255. doi: 10.3389/fpsyg.2014.00255
Carhart-Harris, R., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I.,
et al. (2018). Psychedelics and the essential importance of context.
J. Psychopharmacol. 32, 725–731. doi: 10.1177/0269881118754710
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe,
D. E., et al. (2017). Psilocybin with psychological support for treatment-resistant
depression: six-month follow-up. Psychopharmacology 235, 399–408. doi: 10.
1007/s00213-017-4771-x
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D.,
Kaelen, M., et al. (2016). Psilocybin with psychological support for treatment-
resistant depression: an open-label feasibility study. Lancet Psychiatry 3,
619–627. doi: 10.1016/S2215-0366(16)30065-7
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A.,
and Nutt, D. J. (2015). LSD enhances suggestibility in healthy volunteers.
Psychopharmacology 232, 785–794. doi: 10.1007/s00213-014-3714-z
Carhart-harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M.,
Droog, W., and Nutt, D. J. (2016). Neural correlates of the LSD experience
revealed by multimodal neuroimaging. Proc. Natl. Acad. Sci. U.S.A. 113,
4853–4858. doi: 10.1073/pnas.1518377113
Carhart-Harris, R. L., and Nutt, D. J. (2017). Serotonin and brain function:
a tale of two receptors. J. Psychopharmacol. 31, 1091–1120. doi: 10.1177/
0269881117725915
Forstmann, M., and Sagioglou, C. (2017). Lifetime experience with (classic)
psychedelics predicts pro-environmental behavior through an increase
in nature relatedness. J. Psychopharmacol. 31, 975–988. doi: 10.1177/
0269881117714049
Freud, S. (1920). “Resistance and suppression,” in A General Introduction to
Psychoanalysis, ed. S. Freud (New York, NY: Boni & Liveright). doi: 10.1037/
10667-000
Garcia-Romeu, A., Griffiths, R. R., and Johnson, M. W. (2014). Psilocybin-
occasioned mystical experiences in the treatment of tobacco addiction. Curr.
Drug Abuse Rev. 7, 157–164. doi: 10.2174/1874473708666150107121331
Gasser, P., Kirchner, K., and Passie, T. (2015). LSD-assisted psychotherapy for
anxiety associated with a life-threatening disease: a qualitative study of acute
and sustained subjective effects. J. Psychopharmacol. 29, 57–68. doi: 10.1177/
0269881114555249
Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C.,
Obradovic, M., et al. (2005). Psychological Effects of (S)-Ketamine and N,N-
Dimethyltryptamine (DMT): a double-blind. Pharmacopsychiatry 38, 301–311.
doi: 10.1055/s-2005-916185
Greyson, B. (1983). The near-death experience scale. Construction, reliability, and
validity. J. Nerv. Ment. Dis. 171, 369–375. doi: 10.1097/00005053-198306000-
00007
Greyson, B. (2003). Incidence and correlates of near-death experiences in a cardiac
care unit. Gen. Hosp. Psychiatry 25, 269–276. doi: 10.1016/S0163-8343(03)
00042-2
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A.,
Richards, B. D., et al. (2016). Psilocybin produces substantial and sustained
decreases in depression and anxiety in patients with life-threatening cancer:
a randomized double-blind trial. J. Psychopharmacol. 30, 1181–1197. doi: 10.
1177/0269881116675513
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., and
Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: immediate
and persisting dose-related effects. Psychopharmacology 218, 649–665. doi: 10.
1007/s00213-011-2358-5
Griffiths, R. R., Richards, W. A., McCann, U., and Jesse, R. (2006). Psilocybin can
occasion mystical-type experiences having substantial and sustained personal
meaning and spiritual significance. Psychopharmacology 187, 268–283. doi: 10.
1007/s00213-006-0457-5
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt,
A. L., et al. (2011). Pilot study of psilocybin treatment for anxiety in patients
with advanced-stage cancer. Arch. Gen. Psychiatry 68, 71–78. doi: 10.1001/
archgenpsychiatry.2010.116
Groth-Marnat, G., and Summers, R. (1998). Altered beliefs, attitudes, and
behaviors following near-death experiences. J. Hum. Psychol. 38, 110–125.
doi: 10.1177/00221678980383005
Hartogsohn, I. (2016). Set and setting, psychedelics and the placebo
response: an extra-pharmacological perspective on psychopharmacology.
J. Psychopharmacol. 30, 1259–1267. doi: 10.1177/0269881116677852
Hartogsohn, I. (2017). Constructing drug effects: a history of set and setting. Drug
Sci. Policy Law 3, 205032451668332. doi: 10.1177/2050324516683325
Johnson, M., Richards, W., and Griffiths, R. (2008). Human hallucinogen
research: guidelines for safety. J. Psychopharmacol. 22, 603–620. doi: 10.1177/
0269881108093587
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., and Griffiths, R. R.
(2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of
tobacco addiction. J. Psychopharmacol. 28, 983–992. doi: 10.1177/0269881114
548296
Kaelen, M., Roseman, L., Kahan, J., Santos-Ribeiro, A., Orban, C., Lorenz, R.,
et al. (2016). LSD modulates music-induced imagery via changes in
parahippocampal connectivity. Eur. Neuropsychopharmacol. 26, 1099–1109.
doi: 10.1016/j.euroneuro.2016.03.018
Kellehear, A. (1993). Culture, biology, and the near-death experience.
A reappraisal. J. Nerv. Ment. Dis. 181, 148–156. doi: 10.1097/00005053-
199303000-00002
Kellehear, A., Stevenson, I., Pasricha, S., and Cook, E. (1994). The absence of
tunnel sensations in near-death experiences from India. J. Near Death Stud. 13,
109–113.
Kohr, R. L. (1983). Near-death experiences, altered states, and psi sensitivity. J. Near
Death Stud. 3, 157–176.
Kometer, M., Pokorny, T., Seifritz, E., and Volleinweider, F. X. (2015).
Psilocybin-induced spiritual experiences and insightfulness are associated with
synchronization of neuronal oscillations. Psychopharmacology 232, 3663–3676.
doi: 10.1007/s00213-015-4026-7
Langlitz, N. (2017). Opaque Models: Using Drugs and Dreams to Explore the
Neurobiological Basis of Mental Phenomena, 1st Edn, New York, NY: Elsevier.
Leary, T., Metzner, R., and Alpert, R. (2008). The Psychedelic Experience: A Manual
Based on the Tibetan Book of the Dead. London: Penguin Classics.
Lyons, T., and Carhart-Harris, R. L. (2018). Increased nature relatedness and
decreased authoritarian political views after psilocybin for treatment-resistant
depression. J. Psychopharmacol. 32, 811–819. doi: 10.1177/026988111774
8902
Maclean, K. A., Johnson, M. W., and Griffiths, R. R. (2011). Psilocybin lead
to increases in the personality domain of openness. J. Psychopharmacol. 25,
1453–1461. doi: 10.1177/0269881111420188
Maclean, K. A., Leoutsakos, J.-M. S., Johnson, M. W., and Griffiths, R. R. (2013).
Factor analysis of the mystical experience questionnaire: a study of experiences
occasioned by the hallucinogen psilocybin. J. Sci. Study Relig. 51, 721–737.
doi: 10.1111/j.1468-5906.2012.01685.x.Factor
Martial, C., Cassol, H., Antonopoulos, G., Charlier, T., Heros, J., Donneau, A. F.,
et al. (2017). Temporality of features in near-death experience narratives. Front.
Hum. Neurosci. 11:311. doi: 10.3389/fnhum.2017.00311
Martial, C., Cassol, H., Charland-Verville, V., Merckelbach, H., and Laureys, S.
(2018). Fantasy proneness correlates with the intensity of near-death
experience. Front. Psychiatry 9:190. doi: 10.3389/fpsyt.2018.00190
Maslow, A. H. (1959). Cognition of being in the peak experiences. J. Genet. Psychol.
94, 43–66. doi: 10.1080/00221325.1959.10532434
Metzner, R., Litwin, G. H., and Weil, G. M. (1965). The relation of expectation and
mood to psilocybin reactions: a questionnaire study. Psychedelic Rev. 5, 3–39.
Millière, R. (2017). Looking for the self: phenomenology, neurophysiology and
philosophical significance of drug-induced ego dissolution. Front. Hum.
Neurosci. 11:245. doi: 10.3389/fnhum.2017.00245
Moody, R. (1975). Life After Life: The Investigation of a Phenomenon Survival of
Bodily Death. New York, NY: Harper Collins.
Frontiers in Psychology | www.frontiersin.org 11 August 2018 | Volume 9 | Article 1424
fpsyg-09-01424 August 13, 2018 Time: 9:22 # 12
Timmermann et al. DMT and Near-Death Experiences
Morse, M. L., Venecia, D., and Milstein, J. (1989). Near-death experiences: a
neurophysiologic explanatory model. J. Near Death Stud. 8, 45–53. doi: 10.1007/
BF01076138
Nichols, D. E. (2016). Psychedelics. Pharmacol. Rev. 68, 264–355. doi: 10.1124/pr.
115.011478
Nichols, D. E. (2017). N,N-dimethyltryptamine and the pineal gland: separating
fact from myth. J. Psychopharmacol. 32, 30–36. doi: 10.1177/0269881117736919
Nour, M. M., Evans, L., and Carhart-Harris, R. L. (2017). Psychedelics.
J. Psychoactive Drugs 49, 182–191. doi: 10.1080/02791072.2017.1312643
Nour, M. M., Evans, L., Nutt, D., and Carhart-Harris, R. L. (2016). Ego-Dissolution
and psychedelics: validation of the Ego-Dissolution Inventory (EDI). Front.
Hum. Neurosci. 10:269. doi: 10.3389/fnhum.2016.00269
Noyes, R. (1980). Attitude change following near-death experiences attitude
change following near-death experiences. Psychiatry 43, 234–242. doi: 10.1080/
00332747.1980.11024070
Osório, F., de, L., Sanches, R. F., Macedo, L. R., Santos, R. G., Maia-de-Oliveira,
J. P., et al. (2015). Antidepressant effects of a single dose of ayahuasca in patients
with recurrent depression: a preliminary report. Rev. Bras. Psiquiatr. 37, 13–20.
doi: 10.1590/1516-4446-2014-1496
Ott, U., Reuter, M., Hennig, J., and Vaitl, D. (2005). Evidence for a common
biological basis of the absorption trait, hallucinogen effects, and positive
symptoms: epistasis between 5-HT2a and COMT polymorphisms. Am. J. Med.
Genet. B Neuropsychiatr. Genet. 137B, 29–32. doi: 10.1002/ajmg.b.30197
Pahnke, W. N., and Richards, W. A. (1970). Implications of LSD and experimental
mysticism. J. Psychoactive Drugs 3, 92–108. doi: 10.1080/02791072.1970.
10471366
Palhano-Fontes, F., Barretto, D., Onias, H., Andradre, K. C., Novaes, M., Pessoa,
J. A., et al. (2018). Rapid antidepressant effects of the psychedelic ayahuasca in
treatment-resistant depression: a randomised placebo-controlled trial. Psychol.
Med. 1–9. doi: 10.1017/S0033291718001356 [Epub ahead of print].
Parnia, S., Waller, D. G., Yeates, R., and Fenwick, P. (2001). A qualitative and
quantitative study of the incidence, features and aetiology of near death
experiences in cardiac arrest survivors. Resuscitation 48, 149–156. doi: 10.1016/
S0300-9572(00)00328-2
Peters, E., Joseph, S., Day, S., and Garety, P. (2004). Measuring delusional ideation:
the 21-item Peters et al. Delusions Inventory (PDI). Schizophr. Bull. 30,
1005–1022. doi: 10.1093/oxfordjournals.schbul.a007116
Petitmengin, C. (2006). Describing one’s subjective experience in the second
person: an interview method for the science of consciousness. Phenomenol.
Cogn. Sci. 5, 229–269. doi: 10.1007/s11097-006-9022-2
Petitmengin, C., and Lachaux, J.-P. (2013). Microcognitive science: bridging
experiential and neuronal microdynamics. Front. Hum. Neurosci. 7:617.
doi: 10.3389/fnhum.2013.00617
Ring, K. (1980). Life at Death: A Scientific Investigation of the Near-Death
Experience. New York, NY: Harpr Coward McCann and Geoghenan.
Roseman, L., Nutt, D. J., and Carhart-Harris, R. L. (2018). Quality of acute
psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-
resistant depression. Front. Pharmacol. 8:974. doi: 10.3389/fphar.2017.00974
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., et al.
(2016). Rapid and sustained symptom reduction following psilocybin treatment
for anxiety and depression in patients with life-threatening cancer: a
randomized controlled trial. J. Psychopharmacol. 30, 1165–1180. doi: 10.1177/
0269881116675512
Saavedra-Aguilar, J. C., and Gómez-Jeria, J. S. (1989). A neurobiological model
for near-death experiences. J. Near Death Stud. 7, 205–222. doi: 10.1007/
BF01074007
Sai-Halász, A., Brunecker, G., and Szára, S. (1958). Dimethyl-tryptamin?: ein neues
Psychoticum. Psychiatr. Neurol. 135, 258–301. doi: 10.1159/000131921
Schwaninger, J., Eisenberg, P. R., Kenneth, B., and Weiss, A. N. (2002).
A prospective analysis of near-death experiences in cardiac arrest patients.
J. Near Death Stud. 20, 215–232. doi: 10.1023/a:1015258818660
Shanon, B. (2005). The Antipodes of the Mind: Charting the Phenomenology of the
Ayahuasca Experience. Oxford: Oxford University Press.
Smallwood, J., and Schooler, J. W. (2015). The science of mind wandering:
empirically navigating the stream of consciousness. Annu. Rev. Psychol. 66,
487–518. doi: 10.1146/annurev-psych-010814-015331
Stace, W. (1960). Mysticism and Philosophy. Philadelphia, PA: Lippincott.
Strassman, R. (2001). DMT: The Spirit Molecule. Rochester: Park Street Press.
Strassman, R., and Qualls, C. R. (1994). Dose-response study of N,N-
dimethyltryptamine in humans. i. neuroendocrine, autonomic and
cardiovalscular effects. Arch. Gen. Psychiatry 51, 85–97. doi: 10.1001/archpsyc.
1994.03950020009001
Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H., and Kellner, R. (1994). Dose-
response study of N,N-dimethyltryptamine in humans. II. Subjective effects
and preliminary results of a new rating scale. Arch. Gen. Psychiatry 51, 98–108.
doi: 10.1001/archpsyc.1994.03950020022002
Studerus, E., Gamma, A., Kometer, M., and Vollenweider, F. X. (2012). Prediction
of psilocybin response in healthy volunteers. PLoS One 7:e30800. doi: 10.1371/
journal.pone.0030800
Studerus, E., Gamma, A., and Vollenweider, F. X. (2010). Psychometric evaluation
of the altered states of consciousness rating scale (OAV). PLoS One 5:e12412.
doi: 10.1371/journal.pone.0012412
Tagliazucchi, E., Carhart-Harris, R., Leech, R., Nutt, D., and Chialvo, D. R.
(2014). Enhanced repertoire of brain dynamical states during the psychedelic
experience. Hum. Brain Mapp. 35, 5442–5456. doi: 10.1002/hbm.22562
Tellegen, A., and Atkinson, G. (1974). Openness to absorbing and self-altering
experiences (“absorption”), a trait related to hypnotic susceptibility. J. Abnorm.
Psychol. 83, 268–277. doi: 10.1037/h0036681
Thonnard, M., Charland-Verville, V., Brédart, S., Dehon, H., Ledoux, D.,
Laureys, S., et al. (2013). Characteristics of near-death experiences memories
as compared to real and imagined events memories. PLoS One 8:e57620.
doi: 10.1371/journal.pone.0057620
Timmermann, C., Spriggs, M. J., Kaelen, M., Leech, R., Nutt, D. J., Moran,
R. J., et al. (2017). LSD modulates effective connectivity and neural adaptation
mechanisms in an auditory oddball paradigm. Neuropharmacology doi: 10.
1016/j.neuropharm.2017.10.039 [Epub ahead of print].
Twemlow, S. W., and Gabbard, G. O. (1984). The influence of
demographic/psychological factors and pre-existing conditions on the
near-death experience. Omega 15, 223–235. doi: 10.2190/8VHV-YYEP-DE5M-
HL8N
Vanhaudenhuyse, A., Thonnard, M., and Laureys, S. (2009). “Towards a neuro-
scientific explanation of near-death experiences?,” in Intensive Care Medicine,
ed. J.-L. Vincent (New York, NY: Springer), 961–968. doi: 10.1007/978-0-387-
92278-2_85
Van Lommel, P., Van Wees, R., Meyers, V., and Elfferich, I. (2001). Near-death
experience in survivors of cardiac arrest: a prospective study in the Netherlands.
Lancet 358, 2039–2045. doi: 10.1016/S0140-6736(01)07100-8
Wallace, A. F. C. (1959). Cultural Determinants of Response to Hallucinatory
Experience. Arch. Gen. Psychiatry 1, 58–69. doi: 10.1001/archpsyc.1959.
03590010074009
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Timmermann, Roseman, Williams, Erritzoe, Martial, Cassol,
Laureys, Nutt and Carhart-Harris. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Psychology | www.frontiersin.org 12 August 2018 | Volume 9 | Article 1424
